Group 1 - The Chinese medicine (core stocks) sector experienced a significant rise, with notable increases in stock prices for companies such as Zhendong Pharmaceutical (+19.16%) and Shengwugu (+13.86%) [1][2] - The Ministry of Industry and Information Technology and seven other departments recently issued the "Implementation Plan for the High-Quality Development of the Chinese Medicine (Core Stocks) Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [2][3] Group 2 - The plan outlines six major actions, including improving raw material quality and supply, enhancing manufacturing capabilities, and promoting the revitalization of the national medicine industry, with 15 specific tasks to be implemented [3] - The initiative aims to cultivate 60 high-standard Chinese medicine raw material production bases and support the establishment of 10 major traditional Chinese medicine varieties, while also promoting innovation in Chinese medicine products [3][4] Group 3 - Companies involved in the planting and processing of Chinese medicinal materials are expected to benefit from the establishment of high-standard production bases and the development of modern seed industries, leading to standardized and large-scale growth opportunities [4] - Firms focusing on innovative research and development in Chinese medicine will gain from the encouragement of AI and big data technologies, which will facilitate the transformation of classic formulas into innovative drugs [4][5] Group 4 - The plan includes the construction of 20 smart factories and 10 green factories, which will enhance production efficiency and product quality through digital transformation [4][5] - Companies like Te Yi Pharmaceutical and Hongri Pharmaceutical are positioned to benefit from the promotion of traditional Chinese medicine products and the digitalization of manufacturing processes, respectively [6]

智通财经获悉，2月5日，工信部等八部门联合印发《中药（核心股）工业高质量发展实施方案(2026— 2030年)》，从全产业链视角为中药工业未来五年发展划定"路线图"。《方案》围绕原料供应、创新能 力、制造水平等维度设定量化目标：到2030年培育60个高标准中药原料生产基地、建设5个中药工业守 正创新中心、新培育10个中成药大品种，推动一批医疗机构中药制剂转化为中药创新药，制修订10项中 药工业数智技术相关行业标准，发布20个数智化转型升级典型案例，建设20个智能工厂、培育10个绿色 工厂。 相关概念股： 中国中药（核心股）(00570)：中国中药汇集传统中药精髓，传承了自明代以来开创的"梁仲弘腊丸 馆"、"冯了性"、"同济堂"、"源吉林"等祖铺老号，拥有"冯了性"、"安宁"、"同济堂"3个中华老字 号，"仙灵"、"同济堂"、"仙灵骨葆"、"天江药业"、"德众"5个驰名商标。 同仁堂国药(03613)：同仁堂集团有望新增一家A股上市公司。嘉事堂近日公告称，2月2日，公司股东与 中国北京同仁堂(集团)有限责任公司签署股份转让协议，约定将光大实业、光大健康持有的公司股份以 14.6亿元转让给同仁堂集团。本次交易完成 ...

展望2026年， 国内中药材市场有望在政策引导、需求升级与产业转型的三重驱动下迎来好转。国家药 监局出台的《中药生产监督管理专门规定》将于2026年3月1日起正式实施，与此前已落地的《中药注册 管理专门规定》《中药标准管理专门规定》形成"三位一体"的监管闭环，进一步推动行业规范化、高质 量发展。 结构性分化将成为2026年中药材市场的核心特征。一方面，野生中药材资源枯竭的问题日益凸显，家种 品种价值攀升，北柴胡、关防风等品种供需缺口持续扩大，价格有望稳步上涨；另一方面，在健康消费 升级的背景下，药食同源品种需求呈现刚性增长态势，枸杞、黄芪等品种应用场景不断拓展，将带动原 料需求增加。 2月5日，工信部等八部门联合印发《中药工业高质量发展实施方案(2026—2030年)》，从全产业链视角 为中药工业未来五年发展划定"路线图"。《方案》围绕原料供应、创新能力、制造水平等维度设定量化 目标：到2030年培育60个高标准中药原料生产基地、建设5个中药工业守正创新中心、新培育10个中成 药大品种，推动一批医疗机构中药制剂转化为中药创新药，制修订10项中药工业数智技术相关行业标 准，发布20个数智化转型升级典型案例，建设 ...

智通财经APP获悉，2月5日，工信部等八部门联合印发《中药工业高质量发展实施方案(2026—2030 年)》，从全产业链视角为中药工业未来五年发展划定"路线图"。《方案》围绕原料供应、创新能力、 制造水平等维度设定量化目标：到2030年培育60个高标准中药原料生产基地、建设5个中药工业守正创 新中心、新培育10个中成药大品种，推动一批医疗机构中药制剂转化为中药创新药，制修订10项中药工 业数智技术相关行业标准，发布20个数智化转型升级典型案例，建设20个智能工厂、培育10个绿色工 厂。 《方案》还提到，在原料端，实施"提质稳供行动"，不仅要建设高标准生产基地，还将推广中药材趁鲜 切制工艺，解决产地初加工"小散乱"问题。创新环节，《方案》提出构建经典名方知识图谱、推动医疗 机构制剂转化，破解中药新药研发"周期长、成本高"的难题。在制造能力提升上，《方案》明确加快制 定全国中药饮片炮制规范、配方颗粒国家标准，同时推动智能工厂建设，实现从原料溯源到成品放行的 全流程数据监控。 光大证券医药表示，2026年中药行业的投资逻辑将从"成本修复"转向"价值成长"，政策红利的持续释放 与企业经营效率的提升，将推动行业盈利水平 ...

Group 1 - The core viewpoint of the news is that Te Yi Pharmaceutical (SZ002728) experienced a significant stock price increase due to strong performance forecasts and product demand, leading to a trading halt at a price of 13.19 yuan, with a 10.01% increase and a total market value of 6.767 billion yuan [1] Group 2 - The company forecasts a substantial net profit growth of 241.55%-339.13% for 2025, with a more pronounced growth in non-recurring net profit expected to reach 263.83%-371.64% [1] - In the first three quarters of 2025, the company reported a net profit increase of 985.18% and a non-recurring net profit increase of 2508.06%, alongside a revenue growth of 51.86%, indicating strong financial performance [1] - The core product, cough medicine, has seen significant sales growth, while other products like skin disease blood toxin pills and blood sugar-lowering pills show considerable market potential, contributing to revenue and profit expectations [1] - The company has optimized its marketing channels and successfully transitioned to a "self-operated + promotional service provider" model, enhancing product sales [1] - The traditional Chinese medicine sector has gained market attention recently, with other stocks in the sector also performing well, attracting capital inflow to Te Yi Pharmaceutical due to its outstanding performance [1] - Technical indicators suggest that if short-term moving averages show a bullish arrangement, it may attract more investors to buy [1]

Core Viewpoint - The company is focusing on expanding its market presence and enhancing the efficacy of its core product, the cough remedy "Zhi Ke Bao Pian," while preparing for potential inclusion in medical insurance programs [2][4]. Product Development and Research - The core product "Zhi Ke Bao Pian" has a history of over a century and is effective for various types of chronic cough, with a clinical effectiveness rate of 93% and a low incidence of side effects [2][4]. - Recent studies have been conducted on the product's efficacy against coughs caused by influenza and lung inflammation, with findings published in reputable journals [2]. - The company aims to strengthen its theoretical support for product promotion and consumer education through ongoing research [2]. Market Strategy - The company is implementing a mixed marketing model combining self-operated teams and promotional service providers to expand market coverage [2]. - Efforts are being made to penetrate key national chain pharmacies, deepen partnerships with O2O and B2C e-commerce platforms, and develop third-party channels such as clinics [2]. Financial Performance - For the first three quarters of 2025, the company reported total revenue of 692 million yuan, a year-on-year increase of 51.86%, and a net profit of 65.22 million yuan, up 985.18% [3]. - Sales of "Zhi Ke Bao Pian" have shown steady recovery, reaching 64% of the sales volume compared to the same period in 2023 [3]. Competitive Advantages - The company possesses significant competitive barriers, including advanced extraction technology, a robust patent system, and a strong brand reputation [4][5]. - The product's clinical validation shows high effectiveness rates for specific cough types, further solidifying its market position [4].

Core Viewpoint - The company, Te Yi Pharmaceutical, emphasizes the competitive advantages of its core product, Zhi Ke Bao tablets, which include technological, brand, and efficacy strengths [2]. Group 1: Competitive Advantages - Technological Advantage: The company utilizes advanced extraction processes and quantitative measurement techniques to ensure stable and controllable drug quality. It has applied for multiple invention patents related to the composition, preparation methods, and component testing of Zhi Ke Bao tablets, all of which have been granted, creating a comprehensive patent protection system [2]. - Brand Advantage: Zhi Ke Bao tablets have a century-long history and high market recognition, supported by a loyal customer base [2]. - Efficacy Advantage: Clinical validation shows that Zhi Ke Bao tablets are most effective for treating cold and phlegm-related coughs, with total effective rates of 100% and 95% respectively, while exhibiting low toxicity and quick results [2]. Group 2: Product Strategy - The company is building a "1+N" product matrix centered around Zhi Ke Bao tablets, aiming to continuously enrich its product line and further strengthen its core competitiveness [2].

Core Viewpoint - The company, Te Yi Pharmaceutical, emphasizes the historical significance and efficacy of its core product, Zhi Ke Bao tablets, which have been in use for over a century and are known for their benefits in "clearing the lungs, dispelling phlegm, relieving cough, and alleviating asthma" [2] Company Summary - Te Yi Pharmaceutical's core product, Zhi Ke Bao tablets, has a history of over 100 years [2] - The product is recognized for its therapeutic effects, including lung clearance, phlegm dispelling, cough relief, and asthma alleviation [2]

Core Viewpoint - The company is committed to dual-track research in traditional Chinese medicine (TCM) and chemical drugs, aiming to enhance product quality and market competitiveness through innovation [1] Group 1: Traditional Chinese Medicine (TCM) Development - The company is focusing on the inheritance and development of existing TCM products, conducting clinical and real-world studies for secondary development of key TCM products [1] - The goal is to grow distinctive TCM products, such as cough tablets, skin disease blood detox pills, and blood sugar-lowering pills, into major TCM varieties to enhance brand influence [1] - The company is actively seizing opportunities in the TCM industry by strengthening collaborations with relevant research institutions to develop innovative TCM drugs [1] Group 2: Chemical Drug Research - The company is conducting integrated innovation research on "active pharmaceutical ingredients + formulations," focusing on cutting-edge research for drugs treating major diseases [1] - The approach involves a synergistic model of developing both formulations and active pharmaceutical ingredients to improve overall research efficiency [1]

Core Viewpoint - The company is committed to dual-track research in traditional Chinese medicine (TCM) and chemical drugs, aiming to enhance product quality and market competitiveness through innovation [1] Group 1: Traditional Chinese Medicine (TCM) Development - The company is focusing on the inheritance and development of existing TCM products, conducting clinical and real-world studies for secondary development of key TCM products such as cough tablets, skin disease blood detox pills, and blood sugar-lowering pills [1] - The goal is to grow these TCM products into major categories, enhancing the "Te Yi" brand influence and market competitiveness [1] - The company is actively seizing opportunities in the TCM industry by strengthening collaborations with relevant research institutions to develop innovative TCM drugs [1] Group 2: Chemical Drug Development - The company is conducting integrated innovation research on "active pharmaceutical ingredients + formulations," focusing on cutting-edge research for drugs treating major diseases [1] - The approach involves a synergistic model of developing both formulations and active pharmaceutical ingredients to enhance overall research efficiency [1]